1-(pyridin-3-ylmethyl)-1H-indole | 53924-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(pyridin-3-ylmethyl)-1H-indole
• 英文别名: 1-(3-Pyridylmethyl)indole；1-(pyridin-3-ylmethyl)indole
• CAS: 53924-04-2
• 化学式: C₁₄H₁₂N₂
• 分子量: 208.263
• InChiKey: FHJTWGHTSSSEBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(pyridin-3-ylmethyl)-1H-indole 在 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 6.0h， 生成 N-(3-methyl-1,2-thiazol-5-yl)-2-oxo-2-[1-(pyridin-3-ylmethyl)indol-3-yl]acetamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of N-Heterocyclic Indolyl Glyoxylamides as Orally Active Anticancer Agents

  摘要：

  A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compounds studied, 7 showed the most potent activity of growth inhibition (IC50 = 17-1711 nM) in several human cancer cells. Given orally, compounds 7 and 13 dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.

  DOI：

  10.1021/jm020471r
• 作为产物：
  描述：

  吲哚 在 环戊基甲醚 、 palladium diacetate 、 双(三甲基硅烷基)氨基钾 、 caesium carbonate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 水 为溶剂， 反应 24.0h， 生成 1-(pyridin-3-ylmethyl)-1H-indole
  参考文献：
  名称：

  Suzuki–Miyaura Cross-Coupling of Potassium Trifluoro(N-methylheteroaryl)borates with Aryl and Heteroaryl Halides

  摘要：

  The synthesis of potassium trifluoro(N-methylheteroaryl)borates and their use in cross-coupling reactions with various aryl and heteroaryl halides to construct N-methyl heteroaryl-substituted aromatic and heteroaromatic compounds are reported.

  DOI：

  10.1021/jo4009589

文献信息

• Manganese-Catalyzed Regioselective Dehydrogenative C- versus N-Alkylation Enabled by a Solvent Switch: Experiment and Computation
  作者：Jannik C. Borghs、Viktoriia Zubar、Luis Miguel Azofra、Jan Sklyaruk、Magnus Rueping

  DOI：10.1021/acs.orglett.0c01270

  日期：2020.6.5

  base metal-catalyzed regioselective dehydrogenative alkylation of indolines using readily available alcohols as the alkylating reagent is reported. A single air- and moisture-stable manganese catalyst provides access to either C3- or N-alkylated indoles depending on the solvent used. Mechanistic studies indicate that the reaction takes place through a combined acceptorless dehydrogenation and hydrogen

  报道了使用容易获得的醇作为烷基化试剂的二氢吲哚的第一种贱金属催化的区域选择性脱氢烷基化。单一的空气和水分稳定的锰催化剂取决于所使用的溶剂，可提供C 3-或N-烷基化的吲哚的途径。机理研究表明，该反应通过无受体脱氢和氢自动转移策略的结合而发生。
• Redox Isomerization via Azomethine Ylide Intermediates: <i>N</i>-Alkyl Indoles from Indolines and Aldehydes
  作者：Indubhusan Deb、Deepankar Das、Daniel Seidel

  DOI：10.1021/ol1031359

  日期：2011.2.18

  Indolines react with aromatic and heteroaromatic aldehydes to yield N-alkyl indoles in a benzoic acid catalyzed redox isomerization reaction. Azomethine ylides are intermediates in this process which was established by intramolecular [3 + 2] trapping experiments.

  二氢吲哚在苯甲酸催化的氧化还原异构化反应中与芳族和杂芳族醛反应生成N-烷基吲哚。甲亚甲胺基化物是该过程的中间体，该过程是通过分子内[3 + 2]捕获实验建立的。
• Novel 1-(1-benzyl-1H-indol-3-yl)-N,N,N-trimethylmethanaminium iodides are competitive antagonists for the human α4β2 and α7 nicotinic acetylcholine receptors
  作者：Edwin G. Pérez、Cristian Ocampo、Dominik Feuerbach、Jhon J. López、Guibeth L. Morelo、Ricardo A. Tapia、Hugo R. Arias

  DOI：10.1039/c3md00042g

  日期：——

  This work presents the synthesis and the pharmacological characterization of a series of novel 1-(1-benzyl-1H-indol-3-yl)-N,N,N-trimethylmethanaminium iodide derivatives at the human (h) α7 and α4β2 nicotinic acetylcholine receptors (nAChRs). The inhibitory activity of the compounds was determined by Ca2+ influx assays on cells expressing either the hα7 or hα4β2 nAChR subtype. To determine whether the observed inhibitory activity is mediated by a competitive or non-competitive mechanism, additional radioligand binding assays were performed using [3H]methyllycaconitine, [3H]cytisine, and [3H]imipramine. The results established that the compounds inhibit the nAChRs by a competitive mechanism and that the potencies are higher for the hα7 nAChR compared to that for the hα4β2 nAChR. Substitutions with oxygenated functional groups on the benzene ring increase the receptor selectivity. In particular, the hydroxyl derivatives 4b and 4c present the highest selectivity for the hα7 nAChR subtype. Molecular docking results indicate that the hydroxyl group forms a hydrogen bond with the carbonyl group at α7-Gln116, but not at β2-Phe115, supporting the observed receptor selectivity at the molecular level.

  本研究介绍了一系列新型 1-(1-苄基-1H-吲哚-3-基)-N,N,N-三甲基甲铵碘化物衍生物在人类（h）δ±7 和 δ±4δ²2烟碱乙酰胆碱受体（nAChRs）上的合成和药理学特征。这些化合物的抑制活性是通过对表达 hα7 或 hα4β2 nAChR 亚型的细胞进行 Ca2+ 流入试验确定的。为了确定所观察到的抑制活性是由竞争性机制还是非竞争性机制介导的，还使用 [3H]methyllycaconitine、[3H]cytisine 和 [3H]imipramine 进行了额外的放射性配体结合试验。结果表明，这些化合物通过竞争机制抑制了 nAChRs，而且与 hα4β2 nAChR 相比，它们对 hα7 nAChR 的抑制作用更强。苯环上含氧官能团的取代增加了受体的选择性。特别是羟基衍生物 4b 和 4c 对 hδ7 nAChR 亚型的选择性最高。分子对接结果表明，羟基与δ±7-Gln116 处的羰基形成了氢键，而与δ²2-Phe115 处的羰基没有形成氢键，这在分子水平上支持了观察到的受体选择性。
• C3-Selective Trifluoromethylthiolation and Difluoromethylthiolation of Pyridines and Pyridine Drugs via Dihydropyridine Intermediates
  作者：Xin-Yue Zhou、Ming Zhang、Zhong Liu、Jia-Hao He、Xiao-Chen Wang

  DOI：10.1021/jacs.2c06776

  日期：2022.8.17

  difluoromethylthiolation of pyridines. The method relies on borane-catalyzed pyridine hydroboration for generation of nucleophilic dihydropyridines; these intermediates react with trifluoromethylthio and difluoromethylthio electrophiles to form functionalized dihydropyridines, which then undergo oxidative aromatization. The method can be used for late-stage functionalization of pyridine drugs for the generation

  在此，我们报告了一种 C3 选择性 C-H 三和二氟甲基硫醇化吡啶的方法。该方法依靠硼烷催化的吡啶硼氢化生成亲核二氢吡啶；这些中间体与三氟甲硫基和二氟甲硫基亲电子试剂反应形成功能化的二氢吡啶，然后进行氧化芳构化。该方法可用于吡啶类药物的后期功能化，以产生新的候选药物。
• N-HYDROXYUREA DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：Nikken Chemicals Company, Limited

  公开号：EP0949259A1

  公开（公告）日：1999-10-13

  An N-hydroxyurea derivative having an antiallergic action or anti-inflammatory action having the formula (I): wherein, either one of R1, R3, and R4 represents A, either one of the other groups of R1, R3, and R4 and R2 represents a 3-pyridyl group or 3-pyridylalkyl group, the remaining groups of R1, R2, R3, and R4 independently represent a hydrogen atom, halogen atom, or a substituted or unsubstituted C1 to C8 alkyl group, R5 represents a hydrogen atom or lower alkyl group, R6 represents a hydrogen atom, lower alkyl group, C3 to C7 cycloalkyl group, or a substituted or unsubstituted phenyl group, where the substituent represents a halogen atom, lower alkyl group, or lower alkoxy group, B represents a bond, C1 to C20 alkylene group, C2 to C8 alkenylene group, or C2 to C8 alkynylene group or B-C(R5) represents a C2 to C6 alkylene group having a benzene ring in the middle thereof or its pharmacologically acceptable salt or the hydrate or solvate thereof.

  一种具有抗过敏作用或抗炎作用的 N-羟基脲衍生物，具有式（I）： 其中，R1、R3 和 R4 中的任一基团代表 A，R1、R3 和 R4 的其它基团和 R2 中的任一基团代表 3-吡啶基或 3-吡啶烷基，R1、R2、R3 和 R4 的其余基团独立地代表氢原子、卤素原子或取代或未取代的 C1 至 C8 烷基，R5 代表氢原子或低级烷基，R6 代表氢原子、低级烷基、C3 至 C7 环烷基或取代或未取代的苯基、B 代表键、C1 至 C20 亚烷基、C2 至 C8 烯基或 C2 至 C8 亚炔基，或 B-C(R5)代表中间有苯环的 C2 至 C6 亚烷基或其药理学上可接受的盐或其水合物或溶液。